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Management of dermatological adverse 
events during nivolumab treatment 
ABSTRACT
Programmed death 1 receptor (PD-1) inhibitors, such as nivolumab, are effective in the treatment of advanced 
and metastatic melanoma, as well as in kidney, bladder, and non-small cell lung carcinomas. Adverse events 
of PD-1 inhibitors result mostly from autoimmune mechanisms, include gastrointestinal inflammatory diseases, 
hepatotoxicity, neurotoxicity, endocrinopathies, and skin toxicities. In this article, we highlight the main cutaneous 
adverse events associated with PD-1 inhibitors and provide a set of practical guidelines about their management. 
Additionally, we report a case of nivolumab-induced bullous pemphigoid in a patient with metastatic melanoma.
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Introduction
Nivolumab, a human monoclonal antibody, targets pro-
grammed cell death 1 receptor (PD-1), which is an essential 
negative regulator of the immune response. PD-1 plays a role 
in sustaining peripheral tolerance and preventing autoimmu-
nological reactions, mostly via the inhibition of proliferation, 
activation, and functional effectiveness of T lymphocytes. Ex-
pression of PD-1, as well as its ligands, is present in several 
types of cancer and can modify tumour microenvironment, 
enabling cancer cells to evade immunosurveillance [1]. This 
mechanism is present in the development of melanoma, 
lung, and renal cancer. Role of PD-1 and its ligands in the 
expansion of other types of cancer (such as basal-cell and 
squamous-cell carcinoma or primary cutaneous T-cell lym-
phomas) are currently under investigation [2–4].
Induction of an anticancer immune response that arises 
from PD-1 inhibition can also lead to several immune-relat-
ed adverse events, distinctive to the PD-1 blockade. Antigens 
targeted by T lymphocytes, and therefore responsible for 
autoimmunity induction, have not yet been identified. The 
most common adverse events related to nivolumab include: 
gastrointestinal disorders (diarrhoea, colitis, hepatitis), en-
docrinopathies (hypo- and hyperthyroidism, hypophysitis, 
diabetes, and ketoacidosis), nephritis, autoimmunological 
pneumonitis, and rheumatological disorders [5–7]. 
Nivolumab-associated dermatological 
adverse events 
Immunotherapy-related cutaneous toxicities are 
common. Combined results from the two phase 3 trials 
in melanoma (CA209066 and CA209037) indicate that 
the most common adverse events (≥ 10%) are: fatigue 
(33%), rash (20%), pruritus (18%), diarrhoea (16%), 
and nausea (14%) [5]. Most of the adverse events report-
ed in the studies were mild to moderate (grade 1 or 2). 
Belum et al. [8] presented results from a meta-analysis 
regarding the incidence of dermatological toxicities after 
PD-1 inhibitors. The incidence of nivolumab-associated 
cutaneous adverse events were as follows: 14.3% rash, 
13.2% pruritus, 7.5% vitiligo, 5.3% xeroderma, 2% 
alopecia, 1.5% stomatitis, 1.4% urticarial, 1.4% pho-
tosensitivity reactions, 0.9% hyperhidrosis, and 0.7% 
skin exfoliation. In a single-centre study that included 
82 patients treated with PD-1 inhibitors for metastatic 
melanoma, Hwang et al. [9] reported the following: 
17.1% lichenoid reactions and similar rates of rash, 
14.6% vitiligo, 13.4% actinic keratosis and similar rates 
of seborrheic keratosis, 11% pruritus, 8.5% skin infec-
tions (viral — zoster; tinea, infections of cutaneous 
and subcutaneous tissue — cellulitis), 6.1% new nevi 
and similar rates of squamous-cell carcinomas, 6% 
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folliculitis, 3.7% melanoma metastases, 2.4% bullous 
pemphigoid and similar rates of basal-cell carcinoma, 
and 1.2% primary melanoma and similar rates of hy-
popigmented nevus. Additionally, single cases of acute 
generalised exanthematous pustulosus (AGEP) reaction 
type, photosensitivity reaction, psoriasis, livedo reticu-
laris, and rosacea were described. Presented reports of 
new non-melanocytic skin malignancies are unexpected 
because some previous data suggested beneficial effects 
of PD-1 inhibitors on the development of actinic kerato-
sis, basal-cell, and squamous-cell carcinomas [2, 3, 10]. 
Nayar et al. [11] reported a case of toxic epidermal 
necrolysis after administration of two doses of nivolumab, 
and Cappelli et al. [12] reported a case of secondary sicca 
syndrome with concomitant arthritis. Recently, several 
studies have evaluated the safety of immunotherapy in 
patients with a previous history of autoimmunological dis-
eases. Menzies et al. [13], based on multi-institutional data 
of metastatic melanoma patients treated with PD-1 in-
hibitors, described exacerbations of autoimmunological 
diseases in 38% of the patients, with a 33% incidence of 
grade 1 autoimmunological flair [according to Common 
Terminology Criteria for Adverse Events (CTCAE)] and 
a mean time to flair appearance of 38 days (8–161 days). 
Exacerbations occurred in 52% of the patients with a his-
tory of rheumatological diseases (rheumatoid arthritis, 
scleroderma, Sjögren’s syndrome, and psoriatic arthritis) 
and in 38% of the patients with a history of dermatological 
diseases (e.g. psoriasis). Emphasis should be given to the 
fact that, prior to nivolumab therapy, most of the analysed 
patients had their autoimmunological diseases active (60% 
of patients) and nearly 50% of them received a immuno-
suppressive treatment. About 14% of patients with an 
autoimmunological flair needed oral or intravenous ste-
roids. The character of immune-related adverse events was 
unconventional in nearly 70% of the patients. Interestingly, 
reappearance of previous immunological reactions induced 
by ipilimumab occurred only in 3% of the patients. Novel 
immune-related toxicities associated with PD-1 inhibitors 
appeared in 34% of the patients (grade 1 and 2 intensity 
in 13% and grade 3 intensity in 18% of the cases). 
Table 1 shows the definitions and descriptions of 
chosen nivolumab-associated dermatological adverse 
events (according to 4.0 CTCAE) [14].
Management of the most common 
nivolumab-associated cutaneous 
adverse events
Measles-like maculopapular rash
The estimated rate of incidence is 9.3–14.7% [15, 
16]. The rash usually appears soon after a therapy 
initiation. Histopathological examination of the skin 
biopsy specimen shows the presence of perivascular 
eosinophilic infiltrates, accompanied by an increased eo-
sinophil count in the complete blood count [17]. Grade 
1 (according to CTCAE) maculopapular rash requires 
topical administration of strong corticosteroids one or 
two times daily and oral antihistamines. In grade 2 re-
actions, it is advised to initiate systemic corticosteroids 
in a dose equivalent to 0.5 mg/kg of prednisone [18]. 
Grade 3 reactions require a pause in nivolumab therapy, 
and in grade 4 reactions nivolumab should be stopped 
indefinitely [5]. After a week without improvement in 
symptoms, systemic corticosteroids should be initiated in 
a dose equivalent to 0.5–1 mg/kg of prednisone. Systemic 
corticosteroids should be slowly tapered within a month. 
Topical corticosteroids and oral antihistamines (e.g. 
diphenhydramine or hydroxyzine) should be continued 
until the resolution of symptoms. Treatment inefficiency 
implies an increase in the systemic corticosteroid dose to 
1–2 mg/kg of prednisone, continued until improvement. 
In grade 3–4 skin adverse events, a dermatologist’s 
consultation is indicated because hospitalisation and 
a skin biopsy might be required. Permanent withdrawal 
of the immunotherapy is advised [19]. 
Pruritus and dry skin
Pruritus is a common skin toxicity of nivolumab, with an 
incidence of about 11–18.8% [8, 9, 16]. Grade 1–2 pruritus 
is not a contraindication for nivolumab continuation. Skin 
care in grade 1 pruritus and dry skin includes: application 
of greasy emollients such as petroleum jelly or cholesterol 
based; protection from an UV radiation; administration 
of topical antipruritic medications containing polidocanol, 
menthol, camphor, or pramocaine (one or two times per 
day). Grade 2 pruritus and skin dryness are an indication 
for moderate or strong topical steroids, as well as the addi-
tion of systemic first-generation antihistamines that block 
H1 receptor. If the symptoms are unresponsive, proceed 
with grade 3 recommendations. Treatment of grade 3 pru-
ritus include administration of drugs blocking H1 receptor 
and intermittent low to medium doses of systemic cortico-
steroids (e.g. equivalent to 0.5 mg/kg of prednisone). In the 
case of eczema, lichenification, fissures, and/or secondary 
infections, topical administration of moderately strong 
or strong steroids one or two times per day is advised. 
Alternatively, formulation combining corticosteroids and 
antibiotics might be utilised. Unresponsive or progressing 
adverse events require adjustment of corticosteroid dose 
and/or a pause in nivolumab treatment, according to the 
Summary of Product Characteristics [18]. 
Lichenoid reactions
Lichenoid lesions have a papular appearance, a ten-
dency to merge in larger lesions, and are accompanied 
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Table 1. Chosen dermatological nivolumab-associated adverse events, according to Common Terminology Criteria for 
Adverse Events (4.0 CTCAE) 
Grade Adverse event
1 2 3 4
Bullous diseases
Definition: a disorder 
characterised by an 
inflammation of skin 
with a presence of 
fluid-containing blisters
Asymptomatic; blisters 
covering < 10% BSA
Blisters covering 
10–30% of BSA, limits 
instrumental activities 
of daily living
Blisters covering > 30% 
BSA, limits self-care 
activities of daily living
Blisters covering > 30% 
BSA, electrolytes and 
fluid imbalances; 
hospitalisation in an 
intensive care unit or 
a burn unit indicated
Pruritus Mild intensity and 
limited outreach; 
requires local treatment
Intensive or widespread; 
intermittent; secondary 
skin changes due 
to scratching, limits 
instrumental activities 
of daily living; requires 
systemic treatment
Intensive or widespread; 
constant; limits  
self-care activities  
of daily living or sleep; 
oral corticosteroids  
or immunosuppressive 
treatment indicated
–
Rash maculopapular
Definition: a disorder 
characterised by 
a presence of macules 
(flat) and papules 
(elevated)
Known also as 
a measles-like rash  
One of the most 
common skin toxicities
Often involves upper 
parts of the body and 
spreads centrically, 
accompanied by 
pruritus
Macules/papules 
covering < 10% BSA, 
may be associated with 
symptoms (e.g. pruritus, 
tingling, or tenderness)
Macules/papules 
covering 10–30% BSA, 
may be associated 
with symptoms (e.g. 
pruritus, tingling, or 
tenderness), limits 
instrumental activities 
of daily living
Macules/papules 
covering > 30% BSA 
with or without 
symptoms, limits self-
-care activities of daily 
living 
–
Vitiligo
Definition: patches 
of hypopigmented or 
depigmented skin or 
hair
Toxicity limited only to 
the patients treated for 
melanoma
Hypopigmentation 
or depigmentation 
covering < 10% BSA, 
without negative 
impact on psycho-social 
wellbeing
Hypopigmentation 
or depigmentation 
covering > 10% BSA, 
with negative impact on 
psycho-social wellbeing
– –
Erythema multiforme
Definition: a disorder 
characterised by the 
presence of target 
lesions (macules 
pale in the middle 
surrounded by a rosy or 
red annulus)
Target lesions 
covering < 10% BSA, 
without accompanying 
skin tenderness
Target lesions  
covering 10–30% BSA, 
skin tenderness present; 
possibility of overlapping 
with Stevens-Johnson 
syndrome
Target lesions 
covering > 30% BSA 
with accompanying 
erosions on mucosa of 
oral cavity or mucosa 
of reproductive organs; 
possibility of Stevens-
-Johnson syndrome 
overlapping toxic 
epidermal necrolysis
Target lesions 
covering > 30% BSA, 
electrolytes and 
fluid imbalances, 
hospitalisation in an 
intensive care unit or 
a burn unit indicated, 
corresponds to 
a diagnosis of toxic 
epidermal necrolysis
Æ
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Grade Adverse event
1 2 3 4
Stevens-Johnson 
syndrome
Definition: a disorder 
characterised by 
a separation of dermis 
involving > 10% BSA
Thought to be 
a hypersensitivity 
reaction affecting 
skin and mucous 
membranes
– – Separation of dermis 
involving > 10% BSA 
with accompanying 
erythematous and 
macular changes,  
as well as erosions on 
mucous membranes 
Separation of dermis 
involving 10–30% BSA 
with accompanying 
erythematous and 
macular changes,  
as well as erosions on 
mucous membranes; 
electrolytes and 
fluid imbalances, 
hospitalisation in an 
intensive care unit or 
a burn unit indicated, 
possibility of Stevens-
-Johnson syndrome 
overlapping toxic 
epidermal necrolysis 
Toxic epidermal 
necrolysis
Definition: a disorder 
characterised by 
separation of dermis 
involving > 30% BSA 
The syndrome arises 
from a hypersensitivity 
reaction affecting 
skin and mucous 
membranes
– – – Separation of dermis 
involving ≥ 30% BSA 
with accompanying 
erythematous and 
macular changes,  
as well as erosions on 
mucous membranes, 
electrolytes and 
fluid imbalances, 
hospitalisation in an 
intensive care unit or 
a burn unit indicated
BSA — body surface area
Table 1 cont. Chosen dermatological nivolumab-associated adverse events, according to Common Terminology Criteria 
for Adverse Events (4.0 CTCAE) 
by pruritus [15, 20]. Biopsy examinations reveal the 
presence of PD-1–positive T lymphocytes and lack of 
C3+ lymphocytes. Lichenoid reactions usually develop 
a few months after nivolumab initiation. Typically, no 
modification of the treatment schedule is indicated [20]. 
Severe cases of a lichenoid reactions require systemic 
corticosteroids. Most of the moderate cases resolve after 
topical corticosteroids [15, 20]. 
Vitiligo
Vitiligo is usually generalised, but in some patients 
it is limited to the regions with metastatic involvement. 
It does not require interruption of nivolumab therapy. 
Recommendations include: sun protection; skincare 
with proper moisturisers; topical corticosteroids in 
grade 1 changes; and phototherapy in grade 2 changes 
(although this remains controversial in patients with 
advanced melanoma and should be limited to a specific 
region only, e.g. the face) [8, 15].
Severe drug reactions
Besides the nivolumab-associated dermatological 
adverse events described above, single cases of severe and 
life-threatening dermatological toxicities (grade 3–4 ac-
cording to CTCAE) have been described. These include 
cases of Stevens-Johnson syndrome, toxic epidermal 
necrolysis, drug reactions with eosinophilia and systemic 
symptoms (DRESS) syndrome, or AGEP reactions [8, 
9, 11]. Some of them, despite being potentially fatal, 
can fully resolve with proper systemic management and 
nivolumab withdrawal [6–8, 15–17]. Severe grade 3 and 
4 skin toxicities require: nivolumab interruption and 
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multidisciplinary management (including dermatological 
consultation); hospitalisation in an intensive care unit or 
in a burn unit; rapid treatment of secondary infections; 
proper provision of erosions and wounds; withdrawal of 
all drugs potentially exacerbating skin changes; manage-
ment of fluid and electrolyte imbalances; and sufficient 
analgesia [18]. In patients with a previous history of seri-
ous or life-threatening dermatological reactions to other 
immunotherapeutic drugs, nivolumab usage should be 
considered with extreme caution [5].
In a contrast to the adverse events related to auto-
immunological reactions, which occur from 3–20 weeks 
to even 1–2 years after immunotherapy initiation, toxic 
drug reactions arise sooner, from a period of a few hours 
(as in urticaria) to about three weeks. This phenomenon 
has an important role in the differential diagnosis of 
dermatological adverse events. Valuable clinical insights 
come from the mean period to toxicity occurrence: 
7–21 days for toxic epidermal necrolysis, Stevens-John-
son syndrome, and erythema multiforme; 14–21 days for 
type I rash (viral-like; e.g. maculopapular rash); 1–4 days 
for AGEP reactions; 7–21 days for DRESS syndrome; 
up to few days for photosensitivity reactions.
Nivolumab-induced bullous pemphigoid 
— a case report
A 69-year-old female patient with a metastatic 
mucosal melanoma originating from anal canal was 
admitted to the Department of Dermatology of the 
Military Institute of Medicine due to a presence of 
diffuse skin changes: erythematous lesions, blisters 
with a tense-roof, and erosions partially encrusted with 
haemorrhagic eschars (Fig. 1). Changes show traits of 
photodistribution. Dermatological lesions appeared in 
the eighth month of nivolumab therapy. These were ini-
tially limited to the face and forearms but subsequently 
spread also to the neck, anterior side of the chest, and 
the crura. Intensive pruritus was also present. In the 
ambulatory setting, antibiotics (doxycycline 200 mg/day 
for 10 days), antihistamines, and topical corticosteroids 
were used without improvement. Medical history in-
cluded asthma and arterial hypertension. The patient 
received perindopril, amlodipine, bisoprolol, acetylsali-
cylic acid, and pantoprazole on a daily basis. Diagnostics 
workup for skin changes included: complete blood 
count with a smear (normal results); blood biochemical 
panel (without significant abnormalities); erythrocyte 
sedimentation rate (elevated to 69 mm/h); coagulation 
testing (D-dimer 1.94 µg/mL, fibrinogen 746 mg/dL), 
urinalysis (proteinuria 50 mg/dL and elevated con-
centration of urobilinogen 2.0 mg/dL was detected), 
antinuclear antibodies panel (positive for anti-RO IgG 
antibody 130 U/mL); complement components C3 and 
C4 concentrations (within normal range); evaluation 
of hepatotropic viruses (negative); and proteinogram 
(elevated concentration of alpha-1 fraction — 0.3 g/dL). 
Phototesting results were also negative. Two biopsy 
specimens from changed skin were obtained for histo-
logical examination (microscopic evaluation suggested 
image of interface dermatitis — presence of lichenoid 
infiltrates and subepidermal blistering). An additional 
skin sample was examined under direct immunofluo-
rescence microscopy; deposits of IgG immunoglobulin 
and complement component C3 immunoglobulin were 
discovered within the zone of basement membrane. 
Blood serum was positive for desmoglein 1 and 3 an-
Figure 1. Dermatological changes in the reported case. Visible lesions include: erythematous indurations; singular vesicles on 
an erythematous foundation; numerous erosions and excoriations
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tibodies, as well as for antibodies against antigens of 
epidermal basal membrane (IgG antibodies against 
basal membrane antigens in a titre of 40). Despite the 
pathologist’s suggestion of Interface dermatitis with bul-
lous erythema multiforme anti-PD-1 therapy associated 
(Am J Dermathopathol. 2017; 39, 2), due to the lack 
of clinical, histopathological, and laboratory workup 
correlation, nivolumab-induced bullous pemphigoid 
was diagnosed. For the last two months the patient 
has been treated with prednisone in slowly modified 
doses of 30–20 mg/day (0.375–0.25 mg/kg) and topical 
clobetasol propionate and silver sulfadiazine. As a re-
sult of prolonged treatment with corticosteroids and 
a simultaneous progression of melanoma, the therapy 
with nivolumab was withheld.
Commentary
Autoimmunological bullous diseases are rare ad-
verse events of immunotherapy. Bullous pemphigoid 
is the most common example of autoimmunological 
bullous disease in the general population (80% of cases; 
incidence of 43/1 million in Great Britain) [21]. It usually 
develops in older patients and sometimes can be induced 
by the presence of a malignancy, although the evidence 
regarding correlation of pemphigoid and cancer remains 
equivocal [23]. Only a few cases of a bullous pemphigoid 
induced by nivolumab, pembrolizumab, or durvalumab 
have been reported so far [9, 17]. The pathomechanism 
behind immunotherapy-induced bullous pemphigoid re-
mains unclear and no standard of care exists. A cautious 
approach to the evaluation of different erythematous 
skin changes is advised because pemphigoid lesions 
might be diverse: erythematous indurations; urticaria; 
target lesions; vesicles; and blisters. Lesions are often 
accompanied by pruritus and, in severe cases, by in-
creased eosinophilic content in complete blood count. In 
some variants, pemphigoid may lack the visible bullous 
component and resemble urticaria. Close cooperation 
between the oncologist and dermatologist is required 
for appropriate diagnostic and therapeutic proceedings, 
especially in cases unresponsive to the standard therapy 
based on available guidelines. Diagnostic workup in 
bullous diseases includes histopathological examination 
and direct and indirect immunofluorescence to detect 
the localisation of immunological reactions in skin [17]. 
Common findings in bullous pemphigoid include 
IgG (less often IgE) and C3 deposits in the dermo-epi-
dermal junction, detected in direct immunofluorescence, 
as well as serum antibodies against the antigens of basal 
membrane BP180(NCI6) and BP230 (occasionally also 
other antigens). Clinical findings in drug-induced pem-
phigoid are not different from “classic” pemphigoid, 
although signs and symptoms should resolve, or at least 
improve, after cessation of the responsible drug. How-
ever, some cases may persist for several months after 
drug withdrawal. Prolonged effects of anti-PD-1 therapy, 
arising from a chronic immune activation, might explain 
this phenomenon [23]. A predisposition of some pa-
tients treated with the anti-PD-1 antibodies to develop 
bullous pemphigoid might be due to the presence of 
BP180 antigen in both basal membrane of the epidermis 
and in cancer cells. A pathomechanism leading to the 
production of auto-antibodies, might also be responsible 
for other immunological adverse events in predisposed 
patients [17].
Summary
Growing access to novel oncological therapies is 
resulting in improved patient prognosis. However, 
the diverse and unexpected adverse events induced by 
the new oncological drugs require a multidisciplinary 
approach. The guidelines presented above are based 
on recommendations available in the current medi-
cal literature in English and include management of 
the most common nivolumab-associated skin adverse 
events. Cutaneous adverse events induced by a com-
bination of anti-PD-1 and anti-CTLA-4 antibodies 
(such as ipilimumab) require additional attention 
because their spectrum is more diverse and requires 
intensified treatment. Appropriate management of the 
immunotherapy-induced dermatological adverse events 
have a profound impact on the treatment optimisation 
and on personalising patient care. We harbour a hope 
that the presented guidelines will be helpful in common 
daily practice, for both dermatologists and oncologists. 
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